Glizihenz 60 Tablet MR contains Gliclazide 60mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. The modified-release (MR) formulation ensures a sustained release of the active ingredient, providing prolonged therapeutic effects and enhancing patient compliance by reducing dosing frequency. Glizihenz 60 Tablet MR is typically prescribed as an adjunct to diet and exercise when blood glucose levels cannot be adequately controlled by lifestyle modifications alone. It is essential to monitor blood glucose levels regularly to adjust the dosage appropriately and minimize the risk of hypoglycemia, which is the most common adverse effect associated with sulfonylureas. Caution is advised in patients with renal or hepatic impairment, as well as in those with a history of hypersensitivity to sulfonylureas or related compounds. Glizihenz should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patient education on recognizing symptoms of hypoglycemia and adherence to prescribed therapy is crucial for optimal outcomes. Always consult a healthcare professional before initiating or modifying treatment with Glizihenz 60 Tablet MR.